Northwire Canada EditionThursday, October 15, 2026
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Production / Operations Routine +

Ynvisible Secures SEK 3.0 Million in Grants to Advance Sustainable Manufacturing and Medical E-Paper Applications

Ynvisible Secures Incremental Grant Funding Amidst Continued Dilution and Commercial Scaling Phase

Executive Summary
  • Ynvisible Interactive Inc. secured SEK 3.0 million (approx. CAD$400,000) in grants from Swedish innovation organizations on May 28, 2026.
  • Funding is allocated to two specific projects: R2R-MICROBAT for battery manufacturing and MedPrint for medical-grade e-paper display production.
  • The MedPrint initiative targets a potential capacity of up to 10 million units annually in Norrköping.
  • Management views the funding as validation of their sustainable manufacturing capabilities and expansion into healthcare diagnostics.
  • This follows a series of private placements closed between March and May 2026, totaling over $1.3 million in gross proceeds from equity financing.
Material Impact
  • The grant represents non-dilutive capital which is positive for cash flow but immaterial relative to the company's overall burn rate and recent equity dilution.
  • Previous private placements (March-May 2026) raised approximately $1.3 million in equity, indicating a reliance on shareholder capital rather than commercial revenue to fund operations.
  • The grant amount ($400k) is roughly equivalent to one month of the previous financing rounds and does not materially alter the company's runway or valuation thesis compared to the dilution risk from recent financings.
  • News aligns with historical projections regarding MedPrint scaling; no new commercial contracts were announced alongside this funding, limiting immediate revenue impact.
  • Market reaction has been muted historically on similar announcements (price remained flat around $0.10-$0.12 during financing closings in April/May 2026).
YNV · Price
Company Overview
  • Core Business: Ynvisible develops ultra-low power printed e-paper displays for healthcare, industrial, and automotive applications.
  • Flagship Projects: MedPrint (medical diagnostics) and R2R-MICROBAT (sustainable battery manufacturing).
  • Manufacturing: Operates a roll-to-roll facility in Norrköping, Sweden; utilizes CCL Design for high-volume production transfer to China.
  • Commercial Status: Transitioned from development to commercial execution in 2025 with ~12 confirmed orders generating CAD$800k revenue; pipeline quoted value estimated at CAD$30 million but conversion rate remains unverified.
Read the original news release →

More from Ynvisible Interactive Inc.